David A. Siegel C4 Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,312,200 shares of CCCC stock, worth $6.06 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

1,312,200

Previous 72,700 1704.95%

Holding current value

$6.06 Million

Previous $410,000 2514.63%

% of portfolio

0.03%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$5.3 - $11.0 $6.57 Million - $13.6 Million	1,239,500 Added 1704.95%	1,312,200 $10.7 Million
Q4 2023 Feb 14, 2024	SELL	$1.18 - $6.03 $747,412 - $3.82 Million	-633,400 Reduced 89.7%	72,700 $410,000
Q3 2023 Nov 14, 2023	SELL	$1.81 - $3.89 $543 - $1,167	-300 Reduced 0.04%	706,100 $1.31 Million
Q2 2023 Aug 14, 2023	BUY	$2.75 - $3.77 $841,775 - $1.15 Million	306,100 Added 76.47%	706,400 $1.94 Million
Q1 2023 May 15, 2023	BUY	$3.1 - $9.02 $430,280 - $1.25 Million	138,800 Added 53.08%	400,300 $1.26 Million

Q4 2022 Feb 14, 2023	SELL	$5.42 - $10.24 $54,742 - $103,424	-10,100 Reduced 3.72%	261,500 $1.54 Million
Q3 2022 Nov 14, 2022	SELL	$8.03 - $12.77 $625,537 - $994,783	-77,900 Reduced 22.29%	271,600 $2.38 Million
Q2 2022 Aug 15, 2022	BUY	$5.06 - $26.46 $1.55 Million - $8.13 Million	307,300 Added 728.2%	349,500 $2.64 Million
Q1 2022 May 16, 2022	BUY	$19.99 - $33.23 $843,577 - $1.4 Million	42,200 New	42,200 $1.02 Million

Others Institutions Holding CCCC

# of Institutions

111

Shares Held

49.4M

Call Options Held

455K

Put Options Held

429K

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $226M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account